In our study we confirmed the existence of canonical and non-canonical activation of EphA2 that previously has been reported in different tumor types including NSCLC [20,21,22,23,27,28,30,31,32,34,37,38,39,40,41,42,43,44,45,46]. This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.